Clinical Drug Experience Knowledgebase

Criteria

Inclusion Criteria:

Pain in the knee joint during more than a half day assessed by Visual Analog Pain Scale (score more than 40 mm)
At least three of the following 6 criteria: 20-85 years of age, stiffness lasting less than 30 minutes, crepitus, bony tenderness, bony enlargement, no warmth to the touch
Patient is able to walk without assistance
Patient is familiar with Participant information sheet
Patient signed informed consent form

Non-inclusion Criteria:

Medical history of endoprosthetic knee replacement
Medical history of lower extremity osteotomy
Medical history of knee surgery (including arthroscopy) during preceding 1 year prior to enrollment
Medical history of intraarticular injections during preceding 6 months prior to enrollment
Secondary osteoarthritis of the knee joint: posttraumatic osteoarthritis (developed after clinically significant injury), intra-articular fractures, clinically significant varus or valgus deformities of lower limbs, septic arthritis, joint's inflammatory disorders, gout, advanced chondrocalcinosis, Paget's disease, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary synovial osteochondromatosis, osteonecrosis, hemophilia
Patients prescribed for immunosuppressive treatment
Medical history of systemic autoimmune and inflammatory diseases
Significant weight loss (> 10% of body weight in the previous year) of unknown etiology
Medical history of venous thromboembolism or estimated high risk of venous thromboembolism
Patients prescribed for systemic corticosteroids or other medications treatment with proven impact on bone or cartilage tissue metabolism
Clinically significant abnormalities in results of laboratory tests
Any conditions limiting compliance (dementia, neuropsychiatric disease, drug and alcohol abuse etc.)
Participation in other clinical trials (or administration of investigational drugs) during 3 months prior inclusion
Patients with malignant tumors including postoperative period, patients receiving chemotherapy and/or radiotherapy.
Patient's activated partial thromboplastin time exceeds normal levels more than 1,8 times
Patients prescribed for anticoagulants treatment or patient received anticoagulants at least one hour prior liposuction
Medical history of heterotopic ossifications
Patients prescribed for glycoprotein inhibitors treatment

Exclusion Criteria:

Patient's refusal from the further participation in trial
Patient's refusal from compliance with the requirements of contraception during the participation in research
Chronic kidney disease IV- V stages (creatinine clearance < 30 mL/min estimated by Cockcroft-Gault formula)
Confirmed syphilis, HIV, hepatitis B or C infections

Dropout Criteria:

- Pregnancy